loading page

Therapeutic concentrations of varenicline increase exocytotic release of catecholamines from human chromaffin cells in the presence of nicotine
  • +7
  • Amanda Jiménez-Pompa,
  • Sara Sanz-Lázaro,
  • Arik Hone,
  • Lola Rueda-Ruzafa,
  • José Medina-Polo,
  • Carmen González-Enguita,
  • Jesús Blázquez,
  • Cristobal de los Rios,
  • J McIntosh,
  • Almudena Albillos
Amanda Jiménez-Pompa
Universidad Autónoma de Madrid

Corresponding Author:[email protected]

Author Profile
Sara Sanz-Lázaro
Universidad Autónoma de Madrid
Author Profile
Arik Hone
Universidad Autónoma de Madrid
Author Profile
Lola Rueda-Ruzafa
Universidad Autónoma de Madrid
Author Profile
José Medina-Polo
Instituto de Investigación i+12, Madrid, Spain
Author Profile
Carmen González-Enguita
Fundación Jiménez Díaz, Madrid, Spain
Author Profile
Jesús Blázquez
Hospital Clínico San Carlos, Madrid, Spain
Author Profile
Cristobal de los Rios
Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/ Diego de León, 62, 28006
Author Profile
J McIntosh
University of Utah
Author Profile
Almudena Albillos
Universidad Autónoma de Madrid
Author Profile

Abstract

Background and Purpose: Cardiovascular side effects from varenicline, and a case report of a hypertensive crisis event in a patient with pheochromocytoma being treated with varenicline, have been reported. The goal of the present study was to determine if such side effects might derive, in part, from increased exocytosis of secretory vesicles and subsequent catecholamine release triggered by varenicline in chromaffin cells of the adrenal gland. Experimental Approach: We performed electrophysiological plasma membrane capacitance (Cm) and carbon fiber amperometry experiments to evaluate the effect of varenicline on exocytosis and catecholamine release, respectively, at concentrations reached during varenicline therapy (100 nM). Experiments were conducted in the absence or presence of nicotine, at plasma concentrations achieved right after smoking (250 nM) or steady-state concentrations (110 nM), in chromaffin cells of the adrenal gland obtained from human organ donors or rats. Key Results: Varenicline increased the exocytosis of secretory vesicles and the release of catecholamines from human chromaffin cells in the presence of nicotine. Comparable results were found using rat chromaffin cells; varenicline alone or in the presence of acute or steady-state concentrations of nicotine found in human plasma increased exocytosis. These effects were not due to an increase of Cm or currents triggered by the nicotinic agonists alone. Conclusion and Implications: Therapeutic concentrations of varenicline in the presence of nicotine increased exocytosis and catecholamine release from human chromaffin cells. These results should be taken into account in nicotine addiction therapies when varenicline is used.